Magnetic melamine cross-linked polystyrene-alt-malic anhydride copolymer: Synthesis, characterization, paclitaxel delivery, cytotoxic effects on human ovarian and breast cancer cells.

IF 4.1 4区医学 Q3 ONCOLOGY

Oncology Research Pub Date : 2025-02-28 eCollection Date: 2025-01-01 DOI:10.32604/or.2024.054487

Razieh Momen-Mesgin, Jafar Rezaie, Vahid Nejati, Peyman Najafi Moghadam

{"title":"Magnetic melamine cross-linked polystyrene-alt-malic anhydride copolymer: Synthesis, characterization, paclitaxel delivery, cytotoxic effects on human ovarian and breast cancer cells.","authors":"Razieh Momen-Mesgin, Jafar Rezaie, Vahid Nejati, Peyman Najafi Moghadam","doi":"10.32604/or.2024.054487","DOIUrl":null,"url":null,"abstract":"Objectives: Due to systematic side effects, there is a growing interest in nanoparticle formulation of anticancer drugs. Here, we aimed to synthesize poly (styrene-alt-maleic anhydride) cross-linked by melamine (PSMA/Me) and coated with magnetite nanoparticles (MNPs) PSMA/Me/Fe3O4. In addition, we aimed to load paclitaxel (PTX) into PSMA/Me/Fe3O4 for drug delivery and anticancer investigations.Methods: Novel PSMA/Me was synthesized via free radical copolymerization, coated with Fe3O4, and then used as a transporter for PTX delivery. Fabricated copolymer was characterized using SEM, TGA, and XRD techniques. Drug release rate and loading efficiency were investigated. Human ovarian cancer cells (Skov-3) and breast cancer cells (MCF-7 cells) were incubated with the serial concentration of either free PTX or PSMA/Me/Fe3O4/PTX for cell viability and IC50 analysis for 24 and 48 h.Results: Characterization methods confirmed PSMA/Me copolymer formation. The results showed a significant encapsulation efficiency of 83%. The drug release analysis exhibited that PSMA/Me/Fe3O4/PTX may be considered pH-sensitive nanocarriers. PSMA/Me/Fe3O4/PTX reduced cell viability both dose and time-dependently (p < 0.05). IC50 values of PSMA/Me/Fe3O4/PTX were low when compared to free PTX either 24 or 48 h post-treatment.Conclusions: Our results indicated that PSMA/Me/Fe3O4/PTX was more cytotoxic than PTX in both cancer cells. Findings indicated the potential of PSMA/Me/Fe3O4/PTX as an anticancer nanocarrier system.","PeriodicalId":19537,"journal":{"name":"Oncology Research","volume":"33 3","pages":"665-674"},"PeriodicalIF":4.1000,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11915072/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.32604/or.2024.054487","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Due to systematic side effects, there is a growing interest in nanoparticle formulation of anticancer drugs. Here, we aimed to synthesize poly (styrene-alt-maleic anhydride) cross-linked by melamine (PSMA/Me) and coated with magnetite nanoparticles (MNPs) PSMA/Me/Fe₃O₄. In addition, we aimed to load paclitaxel (PTX) into PSMA/Me/Fe₃O₄ for drug delivery and anticancer investigations.

Methods: Novel PSMA/Me was synthesized via free radical copolymerization, coated with Fe₃O₄, and then used as a transporter for PTX delivery. Fabricated copolymer was characterized using SEM, TGA, and XRD techniques. Drug release rate and loading efficiency were investigated. Human ovarian cancer cells (Skov-3) and breast cancer cells (MCF-7 cells) were incubated with the serial concentration of either free PTX or PSMA/Me/Fe₃O₄/PTX for cell viability and IC₅₀ analysis for 24 and 48 h.

Results: Characterization methods confirmed PSMA/Me copolymer formation. The results showed a significant encapsulation efficiency of 83%. The drug release analysis exhibited that PSMA/Me/Fe₃O₄/PTX may be considered pH-sensitive nanocarriers. PSMA/Me/Fe₃O₄/PTX reduced cell viability both dose and time-dependently (p < 0.05). IC₅₀ values of PSMA/Me/Fe₃O₄/PTX were low when compared to free PTX either 24 or 48 h post-treatment.

Conclusions: Our results indicated that PSMA/Me/Fe₃O₄/PTX was more cytotoxic than PTX in both cancer cells. Findings indicated the potential of PSMA/Me/Fe₃O₄/PTX as an anticancer nanocarrier system.

查看原文本刊更多论文

磁性三聚氰胺交联聚苯乙烯-马来酸酐共聚物：合成、表征、紫杉醇递送、对人卵巢癌和乳腺癌细胞的细胞毒性作用。

目的：由于系统的副作用，人们对纳米颗粒抗癌药物的配方越来越感兴趣。在这里，我们旨在合成三聚氰胺交联的聚苯乙烯-马来酸酐（PSMA/Me），并包被磁铁矿纳米粒子（MNPs） PSMA/Me/Fe3O4。此外，我们的目标是将紫杉醇（PTX）装载到PSMA/Me/Fe3O4中用于药物传递和抗癌研究。方法：采用自由基共聚法制备新型PSMA/Me，包覆Fe3O4，作为PTX的转运体。用SEM、TGA、XRD等技术对合成的共聚物进行了表征。考察了药物的释放速度和装载效率。将人卵巢癌细胞（Skov-3）和乳腺癌细胞（MCF-7细胞）分别以游离PTX或PSMA/Me/Fe3O4/PTX连续浓度孵育24和48 h，观察细胞活力和IC50分析。结果：表征方法证实PSMA/Me共聚物形成。结果表明，包封率为83%。药物释放分析表明PSMA/Me/Fe3O4/PTX可以被认为是ph敏感的纳米载体。PSMA/Me/Fe3O4/PTX降低细胞活力呈剂量和时间依赖性（p < 0.05）。处理后24或48 h， PSMA/Me/Fe3O4/PTX的IC50值均低于未处理PTX。结论：PSMA/Me/Fe3O4/PTX对两种癌细胞的细胞毒性均高于PTX。研究结果表明，PSMA/Me/Fe3O4/PTX具有作为抗癌纳米载体体系的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncology Research 医学-肿瘤学

CiteScore

4.40

自引率

0.00%

发文量

审稿时长

3 months

期刊介绍： Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.